Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221067278> ?p ?o ?g. }
- W4221067278 endingPage "02" @default.
- W4221067278 startingPage "GS2" @default.
- W4221067278 abstract "Abstract Background: Endocrine therapy(ET) plus CDK4/6 inhibitor (i) is the mainstay for the management of estrogenreceptor-positive (ER+)/HER2- mBC. However, most patients (pts) with ER+ mBCeventually experience disease progression, including development of ESR1mutations (mESR1). Elacestrant, an oral SERD, demonstrated preclinical activity,and clinical activity in a phase 1 trial in ER+ mBC, including responses in ptswith prior fulvestrant, CDK4/6i, and mESR1tumors (Bardia JCO 2021).. Methods: EMERALD(NCT03778931), a multicenter, international, randomized, open-label, controlledphase 3 trial, enrolled postmenopausal pts with ER+/HER2- mBC who had received 1-2prior lines of ET and ≤1 line of chemotherapy in the mBC setting and had prior progressionon a ET plus CDK4/6i. Pts were randomized 1:1 to elacestrant (400 mg orallydaily) or standard of care (SOC; investigator’s choice of fulvestrant or anaromatase inhibitor). Stratification factors included mESR1 status (by central lab), priorfulvestrant exposure, and presence of visceral disease. The study had 2 primary endpoints of progression-free survival (PFS), by blindedindependent review committee, in pts withtumors harboring mESR1 and in all pts (mESR1 or mESR1 notdetected). Secondary endpoints included: overall survival (OS), safety, tolerability,and quality of life. An alpha-value of 0.0475 was used to determine statisticalsignificance (2-sided using the truncated Hochberg procedure).. Results: EMERALD enrolled 477 pts(228 with mESR1) between Feb 2019 - Oct 2020, with 239 pts randomized toreceive elacestrant vs 238 pts to SOC. Demographics and disease characteristicswere well-balanced across treatment arms [median age: 63 yrs vs 63.5 yrs; 2prior lines: 46% vs 40.8%; prior CDK4/6i: 100% in both arms]. The study met bothprimary endpoints. There was a 30% reduction in the risk of progression ordeath in the elacestrant arm in all pts (HR=0.697 [95% CI: 0.552, 0.88]; P=0.0018),and a 45% (HR=0.546 [95% CI: 0.387, 0.768]; P=0.0005) reduction in therisk of progression or death in pts with mESR1.For both endpoints, results in key prespecified subgroups, including visceral metastases,number of prior lines of therapy, pretreatment with fulvestrant, and geographicalregion, were consistent with the overall outcome. The PFS rate at 12 months was 22.32% (95% CI: 15.24%, 29.40%)with elacestrant vs 9.42% (95% CI: 4.02%, 14.81%) with SOC in all pts, and26.76% (95% CI: 16.17%, 37.36%) vs 8.19% (95% CI: 1.26%, 15.12%) in the mESR1 subgroup. The prespecified interim OS analysis plannedat the time of the final PFS analysis (allocated2-sided alpha level of 0.0001) demonstrated a trend in favor of elacestrant inall pts (HR=0.751 [95% CI: 0.542, 1.038]; P=0.0821) and in pts with mESR1(HR=0.592 [95% CI: 0.361, 0.958]; P=0.0325). The final OS analysisis expected next year. Common (>10%) treatment-related adverse events (AEs) withelacestrant vs SOC included: nausea (25.3% vs 8.7%), vomiting (11% vs 2.6%), and fatigue (11% vs 7.9%), mostlygrade 1/2. Treatment-emergent AEs leading to discontinuation of elacestrant orSOC were infrequent in both arms (6.3% and 4.4%). Grade ≥3 treatment-relatedAEs in the elacestrant arm vs SOC were 7.2% vs 3.1%, mainly driven by nausea(2.1% vs 0.9%). There were no treatment-related deaths in either group.. Conclusions:Elacestrant is the first oral SERD to demonstrate a statistically significantand clinically meaningful improvement of PFS vs SOC in a randomized phase 3study in pts with ER+/HER2- mBC in the 2nd/3rd-linesetting, including those whose tumors harbor mESR1. Elacestrant was well tolerated and hasthe potential to become the new standard of care for pts with ER+/HER2- mBC. Citation Format: Aditya Bardia, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Peter Vuylsteke, Kathleen K. Harnden, Hung Khong, Judit Kocsis, Florence Dalenc, Virginia Kaklamani, Patrick Dillon, Sunil Babu, Simon Waters, Ines Deleu, José García-Sáenz, Emilio Bria, Marina Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortes, Shubin Liu, Dirk Laurent, Maureen G. Conlan, Francois-Clement Bidard. Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS2-02." @default.
- W4221067278 created "2022-04-03" @default.
- W4221067278 creator A5005286764 @default.
- W4221067278 creator A5007579054 @default.
- W4221067278 creator A5009943754 @default.
- W4221067278 creator A5014744153 @default.
- W4221067278 creator A5017565565 @default.
- W4221067278 creator A5022364267 @default.
- W4221067278 creator A5024519202 @default.
- W4221067278 creator A5024617318 @default.
- W4221067278 creator A5024618610 @default.
- W4221067278 creator A5029469753 @default.
- W4221067278 creator A5030465858 @default.
- W4221067278 creator A5030577122 @default.
- W4221067278 creator A5032612608 @default.
- W4221067278 creator A5034972183 @default.
- W4221067278 creator A5035286316 @default.
- W4221067278 creator A5038563211 @default.
- W4221067278 creator A5041668420 @default.
- W4221067278 creator A5043562974 @default.
- W4221067278 creator A5047918797 @default.
- W4221067278 creator A5051629490 @default.
- W4221067278 creator A5055645665 @default.
- W4221067278 creator A5058791215 @default.
- W4221067278 creator A5068520667 @default.
- W4221067278 creator A5069540694 @default.
- W4221067278 creator A5072458181 @default.
- W4221067278 creator A5078388793 @default.
- W4221067278 creator A5087609764 @default.
- W4221067278 date "2022-02-15" @default.
- W4221067278 modified "2023-10-05" @default.
- W4221067278 title "Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial" @default.
- W4221067278 doi "https://doi.org/10.1158/1538-7445.sabcs21-gs2-02" @default.
- W4221067278 hasPublicationYear "2022" @default.
- W4221067278 type Work @default.
- W4221067278 citedByCount "12" @default.
- W4221067278 countsByYear W42210672782022 @default.
- W4221067278 countsByYear W42210672782023 @default.
- W4221067278 crossrefType "journal-article" @default.
- W4221067278 hasAuthorship W4221067278A5005286764 @default.
- W4221067278 hasAuthorship W4221067278A5007579054 @default.
- W4221067278 hasAuthorship W4221067278A5009943754 @default.
- W4221067278 hasAuthorship W4221067278A5014744153 @default.
- W4221067278 hasAuthorship W4221067278A5017565565 @default.
- W4221067278 hasAuthorship W4221067278A5022364267 @default.
- W4221067278 hasAuthorship W4221067278A5024519202 @default.
- W4221067278 hasAuthorship W4221067278A5024617318 @default.
- W4221067278 hasAuthorship W4221067278A5024618610 @default.
- W4221067278 hasAuthorship W4221067278A5029469753 @default.
- W4221067278 hasAuthorship W4221067278A5030465858 @default.
- W4221067278 hasAuthorship W4221067278A5030577122 @default.
- W4221067278 hasAuthorship W4221067278A5032612608 @default.
- W4221067278 hasAuthorship W4221067278A5034972183 @default.
- W4221067278 hasAuthorship W4221067278A5035286316 @default.
- W4221067278 hasAuthorship W4221067278A5038563211 @default.
- W4221067278 hasAuthorship W4221067278A5041668420 @default.
- W4221067278 hasAuthorship W4221067278A5043562974 @default.
- W4221067278 hasAuthorship W4221067278A5047918797 @default.
- W4221067278 hasAuthorship W4221067278A5051629490 @default.
- W4221067278 hasAuthorship W4221067278A5055645665 @default.
- W4221067278 hasAuthorship W4221067278A5058791215 @default.
- W4221067278 hasAuthorship W4221067278A5068520667 @default.
- W4221067278 hasAuthorship W4221067278A5069540694 @default.
- W4221067278 hasAuthorship W4221067278A5072458181 @default.
- W4221067278 hasAuthorship W4221067278A5078388793 @default.
- W4221067278 hasAuthorship W4221067278A5087609764 @default.
- W4221067278 hasConcept C121608353 @default.
- W4221067278 hasConcept C126322002 @default.
- W4221067278 hasConcept C143998085 @default.
- W4221067278 hasConcept C168563851 @default.
- W4221067278 hasConcept C197934379 @default.
- W4221067278 hasConcept C203092338 @default.
- W4221067278 hasConcept C2775930923 @default.
- W4221067278 hasConcept C2776694085 @default.
- W4221067278 hasConcept C2778375690 @default.
- W4221067278 hasConcept C2780482068 @default.
- W4221067278 hasConcept C2780739268 @default.
- W4221067278 hasConcept C530470458 @default.
- W4221067278 hasConcept C71924100 @default.
- W4221067278 hasConcept C84606932 @default.
- W4221067278 hasConceptScore W4221067278C121608353 @default.
- W4221067278 hasConceptScore W4221067278C126322002 @default.
- W4221067278 hasConceptScore W4221067278C143998085 @default.
- W4221067278 hasConceptScore W4221067278C168563851 @default.
- W4221067278 hasConceptScore W4221067278C197934379 @default.
- W4221067278 hasConceptScore W4221067278C203092338 @default.
- W4221067278 hasConceptScore W4221067278C2775930923 @default.
- W4221067278 hasConceptScore W4221067278C2776694085 @default.
- W4221067278 hasConceptScore W4221067278C2778375690 @default.
- W4221067278 hasConceptScore W4221067278C2780482068 @default.
- W4221067278 hasConceptScore W4221067278C2780739268 @default.
- W4221067278 hasConceptScore W4221067278C530470458 @default.
- W4221067278 hasConceptScore W4221067278C71924100 @default.
- W4221067278 hasConceptScore W4221067278C84606932 @default.
- W4221067278 hasIssue "4_Supplement" @default.
- W4221067278 hasLocation W42210672781 @default.
- W4221067278 hasOpenAccess W4221067278 @default.
- W4221067278 hasPrimaryLocation W42210672781 @default.